Successful management of disseminated superficial actinic porokeratosis with diclofenac sodium 3% gel

Otero-Rivas, M.M.; Rodríguez-Lojo, Romina; Castiñeiras-Mato, I.; Lueiro-Vilariño, Mercedes; Juárez-Casado, Yolanda; Fernández-Díaz, M.L.

doi:10.1111/dth.12444

Cited by 3 publications

(1 citation statement)

References 5 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Traditional topical treatment approaches include topical treatments like diclofenac [10][11][12], imiquimod [13][14] and calcipotriol [15][16][17][18][19]. Oral retinoids [20][21][22] and cryotherapy [15] were used in the past with no any satisfied results.…”

Section: Discussionmentioning

confidence: 99%

Two cases of disseminated superficial actinic porokeratosis (DSAP) and treatment literature review

Thomaidou¹,

Katz²,

Leibovici³

2018

Our Dermatol Online

View full text Add to dashboard Cite

Background: Disseminated superficial actinic porokeratosis (DSAP) is characterized by asymptomatic multiple papules with annular keratotic rim distributed symmetrically on the sun-exposed areas. Many approaches have been proposed in the past for treating DSAP, but the therapy is still a challenge for every physician, mostly because of the frequent relapses of the disease and the multiplicity of the skin lesions. Material and Methods: Two case reports were reported emphasizing the challenges of treatment approach. Therefore, a systemic English literature review was conducted searching Medline database using PubMed Central and Ovid software as search interface to collect evidence based on the various treatment modalities for DSAP. Results: The initial search yielded 146 articles, but only the relevant case reports, case series and studies relating to the treatment of DSAP have been described and summarized in a table. For each different therapy the efficacy of each treatment, side effects, cost-effectiveness and authors' recommendations were reported. Conclusion: Several factors need to be considered prior to physicians' decision of the most appropriate treatment for each patient like age, the extent of body surface area involvement, patients' medical history and social situation, the available resources, the side effects and cost-effectiveness of each treatment. However, l the exact value of each treatment is difficult to determine owing to the lack of controlled studies evaluating their efficacy. Due to few incidences of squamous cell carcinoma, patients need to be followed up and monitored closely for any early detection of recurrence or possible onset of malignancies.

show abstract

Section: Discussionmentioning

confidence: 99%

Two cases of disseminated superficial actinic porokeratosis (DSAP) and treatment literature review

Thomaidou¹,

Katz²,

Leibovici³

2018

Our Dermatol Online

View full text Add to dashboard Cite

show abstract

Poroqueratosis

Kostopoulos-Kanitakis

Kanitakis

2023

EMC - Dermatología

View full text Add to dashboard Cite

Porokeratoses: an update on pathogenesis and treatment

Kostopoulos‐Kanitakis,

Kanitakis

2024

Int J Dermatology

View full text Add to dashboard Cite

Porokeratoses (PK) are a group of uncommon dermatoses characterized by abnormal epidermal differentiation due to a disorder of the mevalonate metabolic pathway. Several clinical subtypes exist that can be associated with the same patient or affect different patients within a family and could, therefore, be different expressions of one disease. All PK subtypes share a common histopathologic finding, the cornoid lamella, a vertical stack of parakeratotic corneocytes embedded in an orthokeratotic horny layer. PK often affects immunosuppressed patients, in whom the course may parallel the level of immunosuppression. The pathogenesis of PK, which had long remained mysterious, has been recently unraveled after discovering pathogenic variants of genes involved in the mevalonate metabolic pathway. The disease is due to germline pathogenic variants of genes of this pathway but requires a second‐hit event to manifest; therefore, PK is considered a dominantly inherited but recessively expressed condition. The prognosis of PK is usually favorable, even though the lesions progress to keratinocyte carcinomas in 7%–16% of patients. The treatment of PK was based on physical (ablative) procedures and various (topical or systemic) treatments, whose efficacy is nevertheless inconsistent and often temporary. The discovery of the metabolic pathway involved in the pathogenesis of PK paved the way for the elaboration of new topical treatments (combination of statins and cholesterol), which are more regularly efficacious compared with older treatments, even though the management of some patients with PK may still be challenging.

show abstract

Successful management of disseminated superficial actinic porokeratosis with diclofenac sodium 3% gel

Cited by 3 publications

References 5 publications

Two cases of disseminated superficial actinic porokeratosis (DSAP) and treatment literature review

Two cases of disseminated superficial actinic porokeratosis (DSAP) and treatment literature review

Poroqueratosis

Porokeratoses: an update on pathogenesis and treatment

Contact Info

Product

Resources

About